Skip to main content

Pathwork Diagnostics, Novartis Team Up for Cancer Biomarker Discovery

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cancer molecular diagnostics developer Pathwork Diagnostics announced today a collaboration with Novartis for the discovery of cancer biomarkers.

The biomarkers will be used as a basis for diagnostics "across a range of cancer types," the Redwood City, Calif.-based firm said in a statement.

Under the terms of the deal, both companies have the rights to develop and commercialize the diagnostic products. Further terms were not disclosed.

Last month Pathwork Diagnostics received clearance from the US Food and Drug Administration for use of its microarray-based Tissue of Origin test with formalin-fixed embedded tissue.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.